This inventor holds 1 USPTO granted patent and 2 published patent applications and 2 EPO patents. Top assignees: Albert-Ludwigs-Universitat Freiburg, Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts. Active years: 2020.
Company Filing History:
1 out of 94 
1 out of 166 
Years Active: 2020
Title: Marcel Schilling: Innovator in Anemia Treatment
Introduction
Marcel Schilling is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of anemia. His innovative work focuses on optimizing dosage regimens for erythropoiesis stimulating agents (ESA) in patients suffering from anemia, especially those with cancer.
Latest Patents
Marcel Schilling holds a patent titled "Methods for the prediction of a personalized ESA-dose in the treatment of anemia." This invention features an integrative pharmacokinetic/pharmacodynamics (PK/PD) mathematical model that calculates the binding behavior of ESAs. The methods provided by this patent enable clinical practitioners to determine ESA binding sites in patients, allowing for optimized treatment plans. The invention also includes methods for screening ESAs that exhibit higher specificity for cells expressing the EPO receptor, such as colony forming units-erythroid (CFU-E) cells.
Career Highlights
Throughout his career, Marcel Schilling has worked with esteemed institutions, including the Deutsches Krebsforschungszentrum and Albert-Ludwigs-Universität Freiburg. His experience in these organizations has contributed to his expertise in the field of anemia treatment and pharmacology.
Collaborations
Marcel has collaborated with notable professionals in his field, including Andreas Raue and Agustin Rodriguez Gonzalez. These partnerships have further enhanced his research and development efforts in the medical domain.
Conclusion
Marcel Schilling's innovative contributions to anemia treatment through his patented methods demonstrate his commitment to improving patient care. His work continues to influence the medical community and offers promising advancements in the treatment of anemia.